Gradalis, Inc.

Gradalis, Inc. is a biotechnology company focused on personalized cancer immunotherapy, leveraging innovative methods to enhance treatment efficacy for patients through tailored solutions. Gradalis, Inc. develops personalized cancer immunotherapy solutions, primarily through its leading product, Vigil®.

The company is headquartered in Carrollton, US. Founded by individuals with experience in the biotechnology sector, Gradalis has raised funding through a Series B round in January 2013, securing USD 24. 00 mn in total. The company has completed one deal to date, with its most recent funding round reflecting the ongoing investment interest in its innovative approaches to cancer treatment.

Gradalis® specializes in personalized cancer immunotherapy, primarily through its flagship product, Vigil®. Vigil® empowers the immune system to combat cancer using a patient’s own tumor cells to create a tailored therapeutic vaccine. This product is aimed at oncology clinics and healthcare providers seeking advanced treatment options and is marketed within the United States and selected international markets, focusing on healthcare institutions committed to improving cancer treatment outcomes. Gradalis® generates revenue primarily through partnerships with healthcare providers and oncology institutions that utilize its Vigil® immunotherapy platform.

The company engages in direct transactions with clients, facilitating the distribution of its personalized immunotherapy products. Revenue is realized as healthcare providers administer Vigil® to patients, with specific pricing structures established in agreements reflecting the unique value of Vigil® in the oncology market. This B2B model allows Gradalis® to maintain close relationships with clients while ensuring access to its innovative cancer therapies. Gradalis, Inc.

plans to leverage its recent Series B financing, which raised USD 24. 00 mn in January 2013, to further develop its product line and enhance market presence. The company aims to launch new formulations of Vigil® and expand into additional markets, targeting both domestic and international oncology clinics. Specific geographic regions for future expansion have yet to be detailed, but Gradalis is committed to increasing its footprint in the global cancer therapeutic market.